CYTOGEN CORP, (CYTO) Stock Research Free Stock Rating

Company Profile

Cytogen Corporation, an oncology-focused biopharmaceutical company, engages in licensing, developing, and commercializing therapeutic and molecular imaging/diagnostic products. The company markets QUADRAMET and PROSTASCINT products. QUADRAMET, a samarium Sm-153 lexidronam injection for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma, and other types of cancer. PROSTASCINT is a capromab pendetide kit for the preparation of Indium In-111 capromab pendetide, a monoclonal antibody-based agent targeting prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. It also engages in the development of therapeutics targeting PSMA, a protein expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. The company’s product candidates and pipeline includes rs PSMA protein vaccine, an in vivo vaccine consisting of recombinant soluble PSMA combined with an immune stimulant to induce an immune response; PSMA viral vector vaccine, an in vivo vaccine that utilizes viral vectors designed to deliver the PSMA gene to immune system cells in order to generate potent and specific immune response; and PSMA monoclonal antibodies, a fully-human monoclonal antibodies that bind to the three-dimensional structure of PSMA as presented on cancer cells, including naked, toxin-linked, and radio-labeled approaches. Cytogen Corporation also has marketing rights to COMBIDEX, an investigational functional molecular imaging agent consisting of iron oxide nanoparticles, which is being developed for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from noncancerous lymph nodes. The compny was founded in 1980. It was incorporated under the name Hybridex, Inc. in March 1980 and changed its name to Cytogen Corporation in April 1980. The company is headquartered in Princeton, New Jersey.

Latest Headlines

CYTOGEN CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerat (EDGAR Online)

CYTOGEN CORP Files SEC form 10-Q, Quarterly Report (EDGAR Online)

CYTOGEN CORP Financials (EDGAR Online Financials)

CYTOGEN CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

CYTOGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (EDGAR Online)

CYTOGEN CORP Files SEC form 10-K, Annual Report (EDGAR Online)

CYTOGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (EDGAR Online)

CYTOGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online)

CYTOGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online)

CYTOGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online)